Who We Are

VEL Sciences is an early-stage, pre-clinical biopharma developing immunotherapeutics against Cancer, antigenically variable pathogens (AVPs), and infectious diseases, such as HCV, HIV, TB, Coronavirus, malaria, influenza, dengue/zika, and other AVPs.

Strategies & Plans

"The patented VEL platform is a revolutionary advancement for developing prophylactic and therapeutic drugs. We intend to disrupt the presently reactive nature of vaccine development with the only proactive platform proven to solve for antigenic variability and efficaciously combat immune escape."


- Keith J. Raphael, Co-Founder and Co-CEO, VEL Sciences.

Scientific Literature

  • Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets

    Servín-Blanco R, Zamora-Alvarado R, Gevorkian G, Manoutcharian K. (corresponding author). Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.   Hum Vaccine Immunother. 2016, 12; 2640-2648.

  • Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response

    Charles-Niño C, Pedroza-Roldan C, Viveros M, Gevorkian G, Manoutcharian K. (corresponding author) Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response. Vaccine. 2011 Jul 18;29(32):5313-21.

  • Variable epitope library-based vaccines: shooting moving targets

    Pedroza-Roldan, C., Charles-Niño, C., Saavedra, R., Govezensky, T., Vaca, L., Avaniss-Aghajani, E., Gevorkian, G., Manoutcharian, K. (corresponding author) Variable epitope library-based vaccines: shooting moving targets. Molecular Immunology 47:270-282, 2009.

  • Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer

    4. Allan Noe Dominguez-Romero, Rubén Zamora-Alvarado, Rodolfo Servín- Blanco, Erendira G. Pérez-Hernándeza, Laura E. Castrillon-Rivera, Maria Elena Munguia, Gonzalo Acero, Tzipe Govezensky, Goar Gevorkian and Karen Manoutcharian (corresponding author). Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Human Vaccines and Immunotherapeutics. 10:11, 3201-3213; November 2014.

  • Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries.

    Servín-Blanco R, Chávaro-Ortiz RM, Zamora-Alvarado R, Martínez-Cortes F, Gevorkian G, Manoutcharian K. (corresponding author). Generation of cancer vaccine immunogens derived from major histocompatibility complex (MHC) class I molecules using variable epitope libraries. Immunol Lett. 2018 Oct 16; 204:47-54. doi: 10.1016/j.imlet.2018.10.008.

  • Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes

    Domínguez-Romero AN, Martínez-Cortés F, Munguía ME, Odales J, Gevorkian G, Manoutcharian K. (corresponding author). Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes. Immunology, 2020.161(2): 123–138. doi: 10.1111/imm.13233.

  • Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model

    Martínez-Cortés F, Servín-Blanco R, Domínguez-Romero AN, Munguía ME, Guzman Valle J, Odales J, Gevorkian G, Manoutcharian K. (corresponding author). Generation of cancer vaccine immunogens derived from Oncofetal antigen (OFA/iLRP) using variable epitope libraries tested in an aggressive breast cancer model. Mol Immunol. 2021 Aug 25;139:65-75. doi: 10.1016/j.molimm.2021.08.013.

  • Antitumor efficacy of MUC1 -derived Variable epitope library treatments in a mouse model of breast cancer

    Antitumor efficacy of MUC1 -derived Variable epitope library treatments in a mouse model of breast cancer. Josue Odales, Rodolfo Servin -Blanco, Fernando Martinez -Cortes, Jesus Guzman Valle, Allan Noe Dominguez -Romero , Goar Gevorkian, Karen Manoutcharian (corresponding author). Vaccine, July, 2022 (accepted paper).

  • Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion?

    Manoutcharian K. (corresponding author)., Guzman Valle J, Gevorkian G. Neoantigen Cancer Vaccines: Real Opportunity or Another Illusion? Arch Immunol Ther Exp (Warsz). 2021 Apr 28;69(1):12. doi: 10.1007/s00005-021-00615-8.

  • Immunogenic properties of immunoglobulin superfamily members within complex biological networks

    Odales J, Guzman Valle J, Martínez-Cortés F, Manoutcharian K. (corresponding author). Immunogenic properties of immunoglobulin superfamily members within complex biological networks. Cell Immunol. 2020 Dec; 358:104235. doi: 10.1016/j.cellimm.2020.104235. Epub 2020 Oct 11.

Learn More

Interested in becoming a commercial partner? Drop us a line and we’ll get back to you!

Contact Us